Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

University of Zurich (UZH)

Status: Unknown

Conditions: Peritoneal Cancer

Treatments: Procedure: CRS and HIPEC

Study type: Observational

Funder types: Other

Identifiers

NCT02741167

HIPEC 2015-0529

Details and patient eligibility

About

The purpose of this study is to assess the dynamics of inflammatory parameters in presence or absence of infectious complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Full description

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the treatment of choice in patients with primary or secondary peritoneal surface malignancies. However the survival benefit is achieved at the cost of increased morbidity and mortality due to an extensive surgery and intraoperative chemo-therapy. Among complications infectious complications are the most common. The early diagnosis of a potential fatal infection is therefore crucial to ensure a good outcome in patients.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consecutive adult patients (more than 18 years) subjected to CRS and HIPEC due to peritoneal malignancy.
• Written informed consent by the participant after information about the research project

Exclusion criteria

• No primary or secondary peritoneal surface malignancy
• No CRS and HIPEC
• Pregnancy
• Younger than 18 years

Trial design

90 participants in 1 patient group

CRS and HIPEC

Description:

Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy

Treatment:

Procedure: CRS and HIPEC